Adipose tissue normally surrounds the major conduit coronary arteries on the surface of the heart. The volume of this perivascular adipose tissue (PVAT) expands with obesity and has been shown to be a strong independent predictor of coronary atherosclerosis. Recent studies implicate PVAT as a ready source of vasoactive factors and inflammatory mediators capable of influencing vasomotor function; however, the vascular effects of coronary PVAT have not been clearly defined. Data from this investigation provide novel evidence that coronary PVAT is capable of releasing factors that initiate/potentiate contraction of coronary arteries independently of the effects on the endothelium. Importantly, the vascular influence of PVAT is specific to anatomic location and is augmented in the setting of obesity. Our findings support that this augmented effect of PVAT is related to alterations in Rho-dependent signaling, increased functional expression of Ca V 1.2 channels, or diminished or altered activity of K + channels in obese coronary arteries. Marked alterations in the expression profile of the coronary PVAT proteome in the setting of obesity uncover new potential therapeutic target proteins (eg, calpastatin) and signaling pathways that may contribute not only to the regulation of vascular smooth muscle tone but also to the initiation of smooth muscle differentiation and proliferation observed in obesity-induced cardiovascular disease. See p 9.
Shortening of the Elastic Tandem Immunoglobulin Segment of Titin Leads to Diastolic Dysfunction
To study the role of increased titin-based passive stiffness in diastolic dysfunction, we studied a new mouse model in which the elastic I band of titin has been shortened as a mechanical analog of increased titin-based stiffness in heart failure with preserved ejection fraction patients. The model displays increased diastolic stiffness, hypertrophy, and exercise intolerance, all common pathological findings in patients with heart failure with preserved ejection fraction. We propose that titin is a possible therapeutic target for ameliorating diastolic stiffening in heart failure with preserved ejection fraction. See p 19.
Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients: National Health and Nutrition Examination Surveys 1988-2010
Hypertension affects 70 million US adults and doubles coronary heart disease (CHD) risk. Antihypertensive pharmacotherapy reduces CHD risk ≈20% to 25%. Strategies to reduce residual CHD risk included treating blood pressure (BP) to lower goals and using different antihypertensive medication classes with limited success. Treating hypercholesterolemia in hypertensive patients reduces residual CHD risk >35%. To facilitate progress in reducing CHD risk, concurrent BP and cholesterol control and factors associated with concomitant control were assessed using National Health and Nutrition Examination Survey data. Approximately 5 in 8 hypertensive patients had high cholesterol. Between 1988 to 1994 and 2005 to 2010, control of low-density lipoprotein cholesterol increased from 9% to 45%, concurrent low-density lipoprotein cholesterol and BP control rose from 5% to 31%, and triple control of low-density lipoprotein cholesterol, nonhigh-density lipoprotein cholesterol, and BP improved from 2% to 27%. Patients who received infrequent healthcare or who were older, black or Hispanic, or who had diabetes mellitus or cardiovascular disease, were less likely to achieve concurrent BP and cholesterol control. Among CHD risk equivalent patients, women were less likely to attain dual control than men. Patients receiving antihypertensive medications and statins were more likely to attain dual control. Strategies to improve concomitant control of BP and cholesterol could include the following: (1) more frequent healthcare visits for patients seen infrequently; and (2) prescribing BP and statin medications to treat BP and cholesterol to goal, especially for patient groups less likely to attain concurrent risk factor control. Policies and programs addressing these opportunities could facilitate progress toward Healthy People 2020 and Millions Hearts CHD prevention goals. See p 29.
Good Prognosis for Pericarditis With and Without Myocardial Involvement: Results From a Multicenter, Prospective Cohort Study
A group of 486 patients with inflammatory myopericardial syndromes (pericarditis, myopericarditis, and perimyocarditis) were followed up for a median follow-up of 36 months. Myocardial involvement was relatively frequent and recorded in one third of patients. Myopericarditis was defined as pericarditis and elevation of cardiac markers of injury without new onset of focal or diffuse depressed left ventricular function by echocardiography or cardiac magnetic resonance; perimyocarditis was diagnosed as pericarditis plus elevation of cardiac markers of injury and evidence of new onset of focal or diffuse depressed left ventricular function by echocardiography or cardiac magnetic resonance. Myocardial inflammatory involvement was confirmed by cardiac magnetic resonance. Clinical clues of myocardial involvement included ST-segment elevation (>75% of cases), arrhythmias, and troponin elevation, which was roughly related to the extent of myocardial involvement but largely overlapping in myopericarditis/ perimyocarditis. Unlike acute coronary syndromes, cardiac troponin elevation was not a negative prognostic marker in myopericarditis/perimyocarditis, and the degree of troponin elevation did not correlate with the likelihood of subsequent recovery. In the setting of myopericarditis/perimyocarditis, the differential diagnosis should especially include acute coronary syndromes, and the presentation in up to 3 of 4 of these patients may simulate an acute coronary syndrome. Left ventricular function was normalized in 90% of the patients. No deaths correlated to pericardial or myocardial involvement were recorded during follow-up. Recurrences generally manifested as recurrent pericarditis and were more common with Volume 128 ◼ Number 1 ◼ July 2, 2013 simple pericarditis. Cardiac magnetic resonance is a useful diagnostic tool for the noninvasive diagnosis of concomitant myocardial inflammatory involvement. See p 42.
Ultralarge von Willebrand Factor Fibers Mediate Luminal Staphylococcus aureus Adhesion to an Intact Endothelial Cell Layer Under Shear Stress
In the past, there was a major shift in both the patient population and the microbial spectrum of infective endocarditis. Staphylococci, especially Staphylococcus aureus, are now the leading cause in industrialized countries. However, in >50% of patients, no previously known heart disease considered a classic risk factor is identified, suggesting alternative, unknown mechanisms for establishing disease. Von Willebrand Factor is luminally secreted on proinflammatory stimulation of endothelial cells and under high shear stress temporarily forms large fibers, entrapping platelets. We hypothesized that S aureus also might be sequestered via this mechanism because it binds to von Willebrand Factor via protein A and to platelets via various surface proteins. In a microfluidic chamber, S aureus adhered in a platelet-and protein A-independent manner to activated endothelial cells. Adherence was ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) susceptible. Wall teichoic acid substantially mediated adherence under high shear stress. Platelets and serum substantially enhanced binding. Using recombinant von Willebrand Factor constructs, we were able to map the involved binding domains. Furthermore, we showed in an intravital microscopy model that circulating S aureus also binds to von Willebrand Factor fibers on activated endothelial cells in vivo. To the best of our knowledge, this is the first study showing that S aureus binds to morphologically intact but activated endothelial cells under high-shear-stress conditions that are thought to exist at the predilection sites for infective endocarditis. This finding sheds light on the initial steps during the pathogenesis of endocarditis and might provide the basis for novel strategies for prevention and treatment by targeting von Willebrand Factor fibrils. See p 50.
Androgen Receptor Promotes Sex-Independent Angiogenesis in Response to Ischemia and Is Required for Activation of Vascular Endothelial Growth Factor Receptor Signaling
In addition to menopause, andropause has been well recognized as a risk factor for cardiovascular diseases. Therefore, sex-specific clinical and experimental data are important in delineating sex-dependent differences in the incidence of and vulnerability to cardiovascular diseases. Here, we show that androgen receptor activation plays an important role in angiogenesis after ischemia regardless of sex. This study identifies the function of the androgen receptor in the compensatory response to ischemia in vivo and defines its mechanism of action as the association of androgen receptor with a vascular endothelial growth factor receptor and activation of proangiogenic downstream pathways. Although beneficial anabolic effects of androgens on various tissues, including bone, skeletal muscles, and central nerves system, are well documented, clinical use of androgens has been limited because of their undesirable side effects. These side effects include the increased risk of prostate cancer in men and hirsutism in women. Recently, selective androgen receptor modulators have been under clinical development, and trials are underway in patients with sarcopenia and cachexia, conditions that are closely associated with cardiovascular complications. On the basis of the present study, we speculate that the appropriately targeted regulation of androgen receptor function in ischemic tissues may lead to novel therapeutic approaches for the treatment of cardiovascular diseases in both sexes. See p 60.
